Abstract 451P
Background
Desmoid tumor (DT) is an aggressive fibroblastic neoplasm with a high propensity for local recurrence. Although multiple therapeutic modalities seem effective for DT, the standard systemic treatment for symptomatic and progressive DT remains controversial. As targeted therapy, tyrosine kinase inhibitors have been recently reported to contribute to the treatment of DT. Thus, the purpose of this study was to assess the efficacy and safety of chemotherapy anlotinib, a novel multi-kinase angiogenesis inhibitor, in patients with DT.
Methods
This retrospective, single-arm clinical trial recruited patients with desmoid tumor who received first-line therap. Patients received anlotinib and methotrexate plus vinorelbine until 12m or disease progression (PD). The primary endpoint was 6m PFS%. Secondary endpoints are PFS, OS, objective response (ORR), disease control rate (DCR) and safety. Tumor response was assessed by the Response Evaluation Criteria in Solid Tumors 1.1 criteria.
Results
Between April 2020 and June 2022, 13 patients were enrolled and 11 of them have received at least one tumor assessment. The median age was 34 (range: 10-67) years, 4 males (30.8%) and 9 females (69.2%). 1 (9.1%) patients achieved a complete response, 2 (18.2%) patients achieved a partial response and 8 patients (72.7%) achieved disease stability. The 6-month PFS rates were 100%. The disease control rate was 100% (11/11) and the objective response rate was 27.3% (3/11). The most common AEs were hypertension (18.2%), leukopenia (18.2%). No ≥grade 3 TRAE was recorded.
Conclusions
Anlotinib combine with chemotherapy was effective against DT with an acceptable safety profile, and significantly slowed the disease progression. Further, multicenter studies with a longer follow-up time are needed to characterize fully the clinical application of anlotinib combine with chemotherapy in DT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
409P - Tertiary lymphoid structures are scarce but associated with BCR clonal expansion, B cell activity and checkpoint inhibitor response in advanced osteosarcoma
Presenter: Qiyuan Bao
Session: Poster viewing 06
410P - The incidence and risk factors of kidney injury in patients receiving immune checkpoint inhibitors: A retrospective observational cohort study
Presenter: Thanawat Suksomboon
Session: Poster viewing 06
411P - Cost-effective analysis of the various cancer screening methods in the community: Pooled analysis of camps of 5 years from 2017-to 2022
Presenter: Suresh Attili
Session: Poster viewing 06
412P - Substance-P in the blood is related with the efficacy of aprepitant for targeted drug-induced refractory pruritus in Chinese malignancy population
Presenter: Fang Gao
Session: Poster viewing 06
413P - Association of concomitant medications on survival outcomes in cancer patients treated with immune checkpoint inhibitors: Analysis of health insurance review and assessment database
Presenter: Soojung Hong
Session: Poster viewing 06
414P - Lessons learnt from clinico-genomic profiling of families with Li Fraumeni Syndrome: The largest case series from the Indian setting
Presenter: Ghazal Tansir
Session: Poster viewing 06
415P - Small cell lung cancer: Epidemiological patterns and mutational profile in the United States
Presenter: Abdallah Allam
Session: Poster viewing 06
416P - Survival outcomes predicted by irAEs on 18F-FDG-PET in response to PD-1 antibody therapy in metastatic melanoma
Presenter: Sarah Lewis
Session: Poster viewing 06
417P - The activity and safety of anlotinib for patients with recurrent malignant glioma: A single-center, retrospective study
Presenter: Xudong Sun
Session: Poster viewing 06
418P - Mutational landscape of non-small cell lung cancer in the United States
Presenter: Mostafa Elsayed
Session: Poster viewing 06